Logo image of AVEO

AVEO PHARMACEUTICALS INC (AVEO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AVEO - US0535883070 - Common Stock

15 USD
0 (0%)
Last: 1/19/2023, 8:09:51 PM
15 USD
0 (0%)
After Hours: 1/19/2023, 8:09:51 PM
Fundamental Rating

3

AVEO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of AVEO have multiple concerns. AVEO is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVEO has reported negative net income.
In the past year AVEO has reported a negative cash flow from operations.
AVEO Yearly Net Income VS EBIT VS OCF VS FCFAVEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

AVEO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVEO Yearly ROA, ROE, ROICAVEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 500 1K

1.3 Margins

Looking at the Gross Margin, with a value of 87.81%, AVEO belongs to the top of the industry, outperforming 91.08% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AVEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVEO Yearly Profit, Operating, Gross MarginsAVEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

AVEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVEO has been increased compared to 1 year ago.
The debt/assets ratio for AVEO is higher compared to a year ago.
AVEO Yearly Shares OutstandingAVEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
AVEO Yearly Total Debt VS Total AssetsAVEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.48, we must say that AVEO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.48, AVEO is doing worse than 68.86% of the companies in the same industry.
AVEO has a Debt/Equity ratio of 0.94. This is a neutral value indicating AVEO is somewhat dependend on debt financing.
AVEO has a worse Debt to Equity ratio (0.94) than 82.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACC9.35%
AVEO Yearly LT Debt VS Equity VS FCFAVEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M

2.3 Liquidity

AVEO has a Current Ratio of 2.37. This indicates that AVEO is financially healthy and has no problem in meeting its short term obligations.
AVEO has a Current ratio of 2.37. This is in the lower half of the industry: AVEO underperforms 78.87% of its industry peers.
AVEO has a Quick Ratio of 2.35. This indicates that AVEO is financially healthy and has no problem in meeting its short term obligations.
AVEO's Quick ratio of 2.35 is on the low side compared to the rest of the industry. AVEO is outperformed by 77.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.35
AVEO Yearly Current Assets VS Current LiabilitesAVEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

AVEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
The Revenue has grown by 269.46% in the past year. This is a very strong growth!
The Revenue has been growing by 76.06% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%

3.2 Future

AVEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.39% yearly.
AVEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.28% yearly.
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
AVEO Yearly Revenue VS EstimatesAVEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
AVEO Yearly EPS VS EstimatesAVEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVEO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 27.40, AVEO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVEO indicates a rather cheap valuation: AVEO is cheaper than 96.09% of the companies listed in the same industry.
AVEO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.70.
Industry RankSector Rank
PE N/A
Fwd PE 27.4
AVEO Price Earnings VS Forward Price EarningsAVEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVEO Per share dataAVEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

AVEO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVEO's earnings are expected to grow with 40.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.26%
EPS Next 3Y40.39%

More info and screens

0

5. Dividend

5.1 Amount

AVEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVEO PHARMACEUTICALS INC

NASDAQ:AVEO (1/19/2023, 8:09:51 PM)

After market: 15 0 (0%)

15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2022-11-07/amc
Earnings (Next)03-13 2023-03-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner Change0%
Market Cap521.45M
Revenue(TTM)94.32M
Net Income(TTM)-29.04M
Analysts50
Price Target15.3 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.92%
Min EPS beat(2)15.97%
Max EPS beat(2)49.87%
EPS beat(4)3
Avg EPS beat(4)18.91%
Min EPS beat(4)-18.6%
Max EPS beat(4)49.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-1.32%
Min Revenue beat(4)-3.54%
Max Revenue beat(4)1.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.59%
EPS NY rev (1m)0%
EPS NY rev (3m)10.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.4
P/S 5.53
P/FCF N/A
P/OCF N/A
P/B 18.08
P/tB 18.08
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)0.55
Fwd EY3.65%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS2.71
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.81%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.35
Altman-Z -4.48
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y59.87%
EPS Next 2Y52.26%
EPS Next 3Y40.39%
EPS Next 5YN/A
Revenue 1Y (TTM)269.46%
Revenue growth 3Y98.59%
Revenue growth 5Y76.06%
Sales Q2Q%100.68%
Revenue Next Year163.12%
Revenue Next 2Y106.24%
Revenue Next 3Y75.28%
Revenue Next 5YN/A
EBIT growth 1Y56.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.21%
OCF growth 3YN/A
OCF growth 5YN/A

AVEO PHARMACEUTICALS INC / AVEO FAQ

What is the fundamental rating for AVEO stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVEO.


What is the valuation status for AVEO stock?

ChartMill assigns a valuation rating of 3 / 10 to AVEO PHARMACEUTICALS INC (AVEO). This can be considered as Overvalued.


How profitable is AVEO PHARMACEUTICALS INC (AVEO) stock?

AVEO PHARMACEUTICALS INC (AVEO) has a profitability rating of 1 / 10.


What is the expected EPS growth for AVEO PHARMACEUTICALS INC (AVEO) stock?

The Earnings per Share (EPS) of AVEO PHARMACEUTICALS INC (AVEO) is expected to grow by 59.87% in the next year.